natgillin/translations-raw huggingface dataset:
NEXGARD SPECTRA 9 mg/ 2 mg chewable tablets for dogs 2–3.5 kg NEXGARD SPECTRA 19 mg/ 4 mg chewable tablets for dogs >3.5–7.5 kg NEXGARD SPECTRA 38 mg/ 8 mg chewable tablets for dogs >7.5–15 kg NEXGARD SPECTRA 75 mg/ 15 mg chewable tablets for dogs >15–30 kg NEXGARD SPECTRA 150 mg/ 30 mg chewable tablets for dogs >30–60 kg afoxolaner / milbemycin oxime
NEXGARD SPECTRA 9 mg/ 2 mg žvečljive tablete za pse 2–3,5 kg NEXGARD SPECTRA 19mg/ 4 mg žvečljive tablete za pse >3,5–7,5 kg NEXGARD SPECTRA 38 mg/ 8 mg žvečljive tablete za pse >7,5 –15 kg NEXGARD SPECTRA 75 mg/ 15 mg žvečljive tablete za pse >15–30 kg NEXGARD SPECTRA 150 mg/ 30 mg žvečljive tablete za pse >30–60 kg afoxolaner/milbemycin oxime
NEXGARD SPECTRA 9 mg/ 2 mg dogs 2–3.5 kg NEXGARD SPECTRA 19 mg/ 4 mg dogs >3.5–7.5 kg NEXGARD SPECTRA 38 mg/ 8 mg dogs >7.5–15 kg NEXGARD SPECTRA 75 mg/ 15 mg dogs >15–30 kg NEXGARD SPECTRA 150 mg/ 30 mg dogs >30–60 kg
NEXGARD SPECTRA 9 mg/ 2 mg psi 2–3,5 kg NEXGARD SPECTRA 19mg/ 4 mg psi >3,5 –7,5 kg NEXGARD SPECTRA 38 mg/ 8 mg psi >7,5 –15 kg NEXGARD SPECTRA 75 mg/ 15 mg psi >15–30 kg NEXGARD SPECTRA 150 mg/ 30 mg psi >30–60 kg
NEXGARD SPECTRA can be used as part of the seasonal treatment of fleas and ticks (replacing a product authorised for the treatment of fleas/ticks only) in dogs with diagnosed concurrent gastrointestinal worm infestations.
NEXGARD SPECTRA je lahko del sezonskega zdravljenja bolhavosti in klopavosti (zamenjava za zdravilo, ki deluje samo proti bolham in klopom) pri psih, ki jim je bila diagnosticirana sočasna infestacija z gastrointestinalnimi glistami.
NEXGARD SPECTRA can be used as part of the seasonal treatment of fleas and ticks (replacing treatment with a monovalent flea and tick product) in dogs with diagnosed concurrent gastrointestinal nematode infestations.
NEXGARD SPECTRA je lahko del sezonskega zdravljenja bolhavosti in klopavosti (zamenjava za monovalentno zdravilo proti bolham in klopom) pri psih, ki jim je bila diagnosticirana infestacija z gastrointestinalnimi nematodi.
Nexgard Spectra is a veterinary medicine that contains the active substances afoxolaner and milbemycin oxime.
Nexgard Spectra je veterinarsko zdravilo, ki vsebuje zdravilni učinkovini afoksolaner in milbemicin oksim.
NEXGARD SPECTRA is not indicated for removal of microfilariae from positive dogs.
Zdravilo NEXGARD SPECTRA ni indicirano za uničenje mikrofilarij pri pozitivnih psih.
Nexgard Spectra is used to treat flea and tick infestations in dogs when prevention of heartworm disease (caused by a roundworm that infects the heart and blood vessels and is transmitted by mosquitoes) and/or treatment of gut worms (hookworms, roundworms and whipworm) is also required.
Zdravilo Nexgard Spectra se uporablja za zdravljenje infestacije z bolhami in klopi pri psih, kadar je potrebno tudi sočasno preprečevanje okužbe s srčno glisto (valjasti črv, ki okuži srce in ožilje, prenašajo pa ga komarji) in/ali zdravljenje okužbe s črevesnimi črvi (kavljastimi črvi, valjastimi črvi in bičeglavci).
NEXGARD SPECTRA kills Dirofilaria immitis larvae up to one month after their transmission by mosquitoes therefore the product should be administered at regular monthly intervals during the time of the year when vectors are present, starting in the month after the first expected exposure to mosquitoes.
NEXGARD SPECTRA ubija ličinke Dirofilaria immitis do enega meseca po njihovem prenosu s komarji, zato je potrebno zdravilo odmerjati redno v mesečnih intervalih v celotnem obdobju izpostavljenosti komarjem.
Nexgard Spectra reduced the number of fleas and ticks by at least 95% and was at least as effective as pyripole.
Zdravilo Nexgard Spectra je zmanjšalo število bolh in klopov za vsaj 95 % in je bilo najmanj tako učinkovito kot piripol.
NexGard tablets are chewable and palatable to most dogs.
Tablete so žvečljive in okusne večini psov.
Nexium Control contains the active substance esomeprazole.
Zdravilo Nexium Control vsebuje zdravilno učinkovino esomeprazol.
Nexium Control gastro-resistant tablets are light pink, oblong, biconvex and engraved with ‘20 mg’ on one side and A/EH on the other side.
Zdravilo Nexium Control gastrorezistentne tablete so svetlorožnate, podolgovate, na obeh straneh izbočene (bikonveksne) tablete z vtisnjeno oznako "20 mg" na eni strani in A/EH na drugi strani.
Nexium Control is similar to a ‘reference medicine’ already authorized in the European Union (EU) containing the same active substance, called Nexium.
Zdravilo Nexium Control je podobno „referenčnemu zdravilu“ Nexium, ki je že odobreno za uporabo v Evropski uniji (EU) in vsebuje enako zdravilno učinkovito.
NexoBrid
Zdravilo NexoBrid
NexoBrid (2 g/100 cm2, corresponding to 0.02 g/cm2) was used as described in section 4.2.
Zdravilo NexoBrid (2 g/100 cm2, kar ustreza 0,02 g/cm2) so uporabili, kot je opisano v poglavju 4.2.
NexoBrid (Number of wounds)
Zdravilo NexoBrid (število ran)
NexoBrid 2 g powder
NexoBrid 2 g prašek
NexoBrid 5 g powder
NexoBrid 5 g prašek
NexoBrid application
Nanos zdravila NexoBrid
NexoBrid contains a mixture of enzymes called “concentrate of proteolytic enzymes enriched in bromelain”, which is extracted from the stem of the pineapple plant.
Zdravilo NexoBrid vsebuje mešanico encimov, imenovano "koncentrat proteolitičnih encimov, obogatenih z bromelainom", ki je ekstrahirana iz stebla rastline ananasa.
NexoBrid gel should be prepared at the patient’s bedside.
Gel zdravila NexoBrid morate priprabiti ob bolnikovi postelji.
NexoBrid is a medicine that contains the active substance ‘concentrate of proteolytic enzymes enriched in bromelain’.
NexoBrid je zdravilo, ki vsebuje zdravilno učinkovino „koncentrat proteolitičnih encimov, obogatenih z bromelainom“.
NexoBrid is not for use in patients younger than 18 years.
Zdravilo NexoBrid ni primerno za uporabo pri bolnikih, mlajših od 18 let.
NexoBrid is not recommended for use on:
Zdravilo NexoBrid se ne priporoča za uporabo pri:
NexoBrid is provided as a powder and gel for gel (powder in a vial (2 g) and gel in a bottle (20 g)), pack size of 1.
Zdravilo NexoBrid je na voljo v obliki praška in gela za gel (prašek v viali (2 g) in gel v steklenički (20 g)), velikost pakiranja 1.
NexoBrid is provided as a powder and gel for gel (powder in a vial (5 g) and gel in a bottle (50 g)), pack size of 1.
Zdravilo NexoBrid je na voljo v obliki praška in gela za gel (prašek v viali (5 g) in gel v steklenički (50 g)), velikost pakiranja 1.
NexoBrid may:- increase the effects of certain medicines that are inactivated by a liver enzyme called CYP2C8 and CYP2C9.
Zdravilo NexoBrid lahko: poveča učinke nekaterih zdravil, ki jih jetrna encima, imenovana CYP2C8 in CYP2C9, deaktivira.
NexoBrid powder and gel must be mixed thoroughly until a uniform, slightly tan to slightly brown mixture is obtained.
Zdravilo NexoBrid prašek in gel morate dobro premešati, da dobite enakomerno, rahlo svetlorjavo do rjavkasto mešanico.
NexoBrid powder is then transferred into the corresponding gel bottle.
Prašek zdravila NexoBrid nato prenesite v ustrezno stekleničko z gelom.
NexoBrid should be used with caution in patients with cardiopulmonary and pulmonary disease, including pulmonary burn trauma and suspected pulmonary burn trauma.
Zdravilo NexoBrid je treba pri bolnikih z boleznijo src in pljuč ali boleznijo pljuč, vključno s poškodbami pljuč zaradi opeklin in sumom na poškodbe pljuč zaradi opeklin uporabiti previdno.
NexoBrid should not be applied to more than 15% (one eighth) of the total body surface.
Zdravila NexoBrid se ne sme nanesti na več kot 15 % (ena osmina) celotne površine telesa naenkrat.
NexoBrid should not be applied to more than 15% Total Body Surface Area (TBSA) (see also section 4.4, Coagulopathy).
V enem postopku nanašanja zdravila NexoBrid ne nanesite na več kot 15 % celotne površine telesa (CPT) (glejte tudi poglavje 4.4, Koagulopatija).
NexoBrid was applied once to the burn wound at a dose of 2 g NexoBrid Powder/20 g gel/100 cm2 of skin.
Zdravilo NexoBrid so na opeklinsko rano nanesli enkrat v odmerku 2 g zdravila NexoBrid prašek/20 g gela/100 cm2 kože.
NexoBrid will be applied to a wound area that is clean, blister free, and moist.
Zdravilo NexoBrid vam bo zdravnik nanesel na predel rane, ki je čist, brez mehurjev in vlažen.
Next injection
Naslednje injiciranje
NextPharma SAS 17, Route de Meulan F-78520 Limay France
NextPharma SAS 17, Route de Meulan F-78520 Limay Francija
NextPharma SAS, 17 Route de Meulan, F-78520 Limay, France.
NextPharma SAS, 17 Route de Meulan, F-78520 Limay, Francija
NF-kB is a transcription factor whose activation is required for many aspects of tumourigenesis, including cell growth and survival, angiogenesis, cell-cell interactions, and metastasis.
NF- kB je transkripcijski faktor, katerega aktivacija je potrebna za mnoge stopnje nastanka tumorja, npr. za rast in preživetje celic, angiogenezo, interakcije med celicami in metastaziranje.
nfections and infestations*
Infekcijske in parazitske bolezni
NFV + NRTIs
NFV + NRTI-ji
nger
ljenja
nger
nja nja
nger
SureClick x1
nger nger
oljenja oljenja
NHL with CNS involvement
NHL s prizadetostjo osrednjega živčevja
nicardipine
maravirok
Nicardipine
nifedipin
Nicardipine
Priporočamo
Nicotine replacement therapy (NRT
Nadomestno zdravljenje z nikotinom (NRT)
nicotinic acid (high dosages) and nicotinic acid derivatives, laxatives (long term use),
nikotinska kislina (veliki odmerki) in derivati nikotinske kisline, odvajala (dolgotrajna uporaba),
nicotinic acid (high doses) and nicotinic acid derivatives, laxatives (long-term use),
nikotinska kislina (veliki odmerki) in derivati nikotinske kisline, odvajala (dolgotrajna uporaba),
nicotinic acid (to treat high cholesterol level)
nikotinska kislina (za zdravljenje zvišane ravni holesterola)
Nicotinic acid is excreted in human breast milk.
Nikotinska kislina se izloča v materino mleko.
Nicotinic acid: There is no pharmacokinetic data in the elderly (≥ 65 years).
Nikotinska kislina: Farmakokinetičnih podatkov za starejše (≥ 65 let) ni.
Niemann-Pick type C disease.
Niemann-Pickova bolezen tipa C.
nifedipine (used to treat high blood pressure);
nifedipin (uporablja se za zdravljenje visokega krvnega tlaka);
night sweats
nočno znojenje,
night sweats (1.0% vs 1.0%)
nočno potenje (1,0% v primerjavi z 1,0%)
night sweats acne (pimples)
nočno znojenje, akna (mozoljavost).
night sweats enlarged lymph nodes in the neck or groin
nočno potenje povečane bezgavke v vratu ali dimljah
night sweats tissue necrosis (death of tissue cells) in the affected arm or leg, which is severe enough to require amputation
nočno znojenje; nekroze tkiva (odmiranje celic tkiva) v prizadeti roki ali nogi, ki je tako hudo, da je potrebna amputacija.
Night sweats Urticaria Dermatitis contact Cold sweat
nočno znojenje urtikarija
Night sweats Urticaria Dermatitis contact Cold sweat
nočno znojenje urtikarija kontaktni
Night sweats Urticaria Dermatitis contact Cold sweat
nočno znojenje, urtikarija, kontaktni dermatitis, hladen znoj,
night sweats,
nočno potenje,
night sweats, back pain, tiredness, shivering, tenderness, chest pain, sudden fever and flu-like symptoms (generalised aches and pains) elevation of the liver enzymes, abrasion.
nočno znojenje, bolečine v hrbtu, utrujenost, drgetanje, občutljivost, bolečine v prsnem košu, nenadna vročina in simptomi, podobni gripi (generalizirane bolj ali manj izrazite bolečine) zvišanje jetrnih encimov, abrazija
Night sweats, Dry skin
/ preferenčni izraz
Night sweats, Dry skin
dispneja
Night sweats, Dry skin
nočno znojenje, suha koža
night sweats, excessive sweating, hot flushes
nočno potenje, prekomerno potenje, vročinski oblivi
night sweats, hives, cold sweats, sensitivity to sunlight, increased tendency to bruise
nočno potenje, koprivnica, hladen znoj, občutljivost na sončno svetlobo, povečana nagnjenjenost k nastanku modric
night sweats, hives, cold sweats, sensitivity to sunlight, increased tendency to bruise
nočno potenje, koprivnica, hladen znoj, občutljivost na sončno svetlobo, povečano nagnjenje k modricam
night sweats, hives, cold sweats, sensitivity to sunlight, increased tendency to bruise;
nočno potenje, koprivnica, hladen znoj, občutljivost na sončno svetlobo, povečano nagnjenje k modricam;
night sweats, increased sweating
nočno potenje, povečano potenje
night sweats;
nočno potenje;
nightmare
neznana
nightmare
nočna mora
Nightmare
nočne more
Nightmare
nočne more,
Nightmare and insomnia are listed as an ADR in the timolol Product Information.
Nočne more in nespečnost so navedene kot neželeni učinki v informacijah o zdravilni učinkovini timolol.
Nightmare Catatonia
nočne more katatonija
nightmare, depression, deafness, vertigo
nočne more, depresija, naglušnost, vrtoglavica
Nightmares
nočne more
nightmares
nočne more,
Nightmares
nočnimi morami,
Nightmares*
nočne more
Nighttime sleep on 25% most symptomatic nights
Spanje ponoči v 25 % noči z najbolj izraženimi simptomi
Nighttime sleep on 25% most symptomatic nights (minutes)(3)
Spanje ponoči v 25 % noči z najbolj izraženimi simptomi (v minutah)(3)
Nilotinib acts by blocking the protein kinase called Bcr-Abl kinase.
Nilotinib deluje tako, da zavira protein-kinazo, imenovano Bcr-Abl kinaza.
Nilotinib has been evaluated in safety pharmacology, repeated dose toxicity, genotoxicity, reproductive toxicity, phototoxicity and carcinogenicity (rats and mice) studies.
Zdravilo Nilotinib so ocenjevali v farmakoloških študijah varnosti, študijah toksičnosti ponovljenih odmerkov, genotoksičnosti, vpliva na sposobnost razmnoževanja, fototoksičnosti in karcinogenosti (pri podganah in miših).
Nilotinib has little or no effect against the majority of other protein kinases examined, including Src, except for the PDGF, KIT and Ephrin receptor kinases, which it inhibits at concentrations within the range achieved following oral administration at therapeutic doses recommended for the treatment of CML (see Table 4).
Nilotinib le malo oziroma sploh ne učinkuje proti večini drugih preizkušanih protein kinaz, vključno s Src, kar pa ne velja za PDGF, KIT in Ephrin receptor kinaze, ki jih zavira v okviru koncentracij, doseženih s peroralno aplikacijo priporočenih terapevtskih odmerkov za zdravljenje KML (glejte preglednico 4).
Nilotinib is the main circulating component in the serum.
Od vseh presnovnih stopenj kroži v serumu v glavnem nilotinib.
Nilotinib resistant mutationsc
mutacije, neodzivne na nilotinibc
Nimenrix
Nimenrix 1 odmerek
Nimenrix
Nimenrix 2 odmerka
Nimenrix
rSBA
Nimenrix 1 dose
Nimenrix 1 odmerek
Nimenrix 2 doses
Nimenrix 2 odmerka
Nimenrix booster vaccination after priming in toddlers, children, adolescents and adults: For subjects primed with Nimenrix aged 1 year and above and boosted with Nimenrix 4 or 5 years later, more than 99.0% of all subjects achieved post-booster SBA titres  1:8 for both assays (studies MenACWY-TT- 062, 048, 059, 088).
Cepljenje z obnovitvenim odmerkom cepiva Nimenrix po osnovnem cepljenju pri malčkih, otrocih, mladostnikih in odraslih: pri preskušancih, ki so prejeli osnovno cepljenje s cepivom Nimenrix v starosti 1 leta ali več in obnovitveno cepljenje s cepivom Nimenrix 4 ali 5 let kasneje, je več kot 99,0 % vseh preskušancev po obnovitvenem odmerku doseglo titre SBA  1:8 v obeh preskusih (študije MenACWY-TT-062, 048, 059, 088).
Nimenrix can also be given concomitantly with combined diphtheria - tetanus - acellular pertussis vaccines, including combination DTaP vaccines with hepatitis B, inactivated polio or Haemophilus influenzae type b, such as DTaP-HBV-IPV/Hib vaccine and 13-valent pneumococcal conjugate vaccine in the second year of life.
V drugem letu življenja se cepivo Nimenrix lahko uporabi sočasno s kombiniranimi cepivi proti davici-tetanusu-oslovskemu kašlju (acelularno), vključno s kombinacijo cepiv DTaP in cepiv proti hepatitisu B, otroški paralizi (inaktivirano) ali Haemophilusu influenzae tipa b, npr. cepivom DTaP- HBV-IPV/Hib in 13-valentnim pnevmokoknim konjugiranim cepivom.
Nimenrix can be given concomitantly with any of the following vaccines: hepatitis A (HAV) and hepatitis B (HBV) vaccines, measles - mumps - rubella (MMR) vaccine, measles - mumps - rubella - varicella (MMRV) vaccine, 10-valent pneumococcal conjugate vaccine or unadjuvanted seasonal influenza vaccine.
Cepivo Nimenrix se lahko daje sočasno z vsemi naslednjimi cepivi: s cepivi proti hepatitisu A (HAV) in hepatitisu B (HBV), cepivom proti ošpicam-mumpsu-rdečkam (MMR), cepivom proti ošpicam- mumpsu-rdečkam-noricam (MMRV), z 10-valentnim konjugiranim pnevmokoknim cepivom in cepivom proti sezonski gripi brez adjuvansa.
Nimenrix elicited bactericidal responses against all four groups that were similar in terms of % with rSBA titre ≥8 and GMT after one or two doses (Table 3).
Cepivo Nimenrix je povzročilo baktericidne odzive proti vsem štirim skupinam, ki so bili (kar zadeva odstotke s titri rSBA ≥ 8 in GMT) podobni po enem ali dveh odmerkih (preglednica 3).
Nimenrix induces the production of bactericidal antibodies against capsular polysaccharides of group A, C, W-135 and Y when measured by assays using either rabbit complement (rSBA) or human complement (hSBA).
Cepivo Nimenrix povzroči nastanek baktericidnih protiteles proti kapsularnim polisaharidom skupin A, C, W-135 in Y, merjenih s preskusi, ki uporabljajo bodisi kunčji (rSBA) bodisi humani (hSBA) komplement.
Nimenrix is a vaccine which helps protect against infections caused by bacteria (germs) called “Neisseria meningitidis" types A, C, W-135 and Y.
Cepivo Nimenrix pomaga pri zaščiti pred okužbami, ki jih povzročajo bakterije (klice), imenovane “Neisseria meningitidis" tipov A, C, W-135 in Y.
Nimenrix is a vaccine.
Zdravilo Nimenrix je cepivo.
Nimenrix is indicated for active immunisation of individuals from the age of 12 months and above against invasive meningococcal diseases caused by Neisseria meningitidis group A, C, W-135, and Y.
Cepivo Nimenrix je indicirano za aktivno imunizacijo posameznikov, starih 12 mesecev ali več, proti invazivnim meningokoknim boleznim, ki jih povzroča Neisseria meningitidis skupin A, C, W-135 in Y.
Nimenrix is not likely to affect your ability to drive or use machines.
Ni verjetno, da bi cepivo Nimenrix vplivalo na vašo sposobnost za upravljanje vozil ali strojev.
Nimenrix is used to protect adults, adolescents and children from the age of 12 months against invasive meningococcal disease caused by four groups of the bacterium N. meningitidis (group A, C, W-135, and Y).
Cepivo Nimenrix se uporablja za zaščito odraslih, mladostnikov in otrok, starejših od 12 mesecev, pred invazivno meningokokno boleznijo, ki jo povzročajo štiri skupine bakterije N. meningitidis (skupina A, C, W-135 in Y).
Nimenrix is usually given as a single injection, preferably into the shoulder muscle.
Navadno se injicira v enem odmerku, po možnosti v ramensko mišico.
Nimenrix is well tolerated and the CHMP considered that it can be safely given together with other routinely used vaccines in the different age groups.
Ker bolniki zdravilo Nimenrix dobro prenašajo, je Odbor menil, da se lahko varno uporablja skupaj z drugimi rutinskimi cepivi pri različnih starostnih skupinah.
Nimenrix may be given as a booster dose in individuals who have previously received primary vaccination with Nimenrix or other conjugated or plain polysaccharide meningococcal vaccine (see sections 4.4 and 5.1).
Cepivo Nimenrix je mogoče uporabiti kot obnovitveni odmerek pri posameznikih, ki so predhodno prejeli osnovno cepljenje s cepivom Nimenrix ali drugimi konjugiranimi ali navadnimi polisaharidnimi meningokoknimi cepivi (glejte poglavji 4.4 in 5.1).
Nimenrix may be given as a booster dose in individuals who have previously received primary vaccination with Nimenrix or other conjugated or plain polysaccharide meningococcal vaccines (see sections 4.4 and 5.1).
Cepivo Nimenrix je mogoče uporabiti kot obnovitveni odmerek pri posameznikih, ki so predhodno prejeli osnovno cepljenje s cepivom Nimenrix ali drugimi konjugiranimi ali navadnimi polisaharidnimi meningokoknimi cepivi (glejte poglavji 4.4 in 5.1).
Nimenrix may be given to adults, adolescents and children over the age of 12 months.
Cepivo Nimenrix se lahko daje odraslim, mladostnikom in otrokom, starejšim od 12 mesecev.
Nimenrix powder and solvent for solution for injection in ampoule Meningococcal group A, C, W-135, and Y conjugate vaccine
Nimenrix prašek in vehikel za raztopino za injiciranje v ampuli cepivo proti meningokokom skupin A, C, W-135 in Y, konjugirano
Nimenrix powder and solvent for solution for injection in pre-filled syringe Meningococcal group A, C, W-135, and Y conjugate vaccine
Nimenrix prašek in vehikel za raztopino za injiciranje v napolnjeni injekcijski brizgi cepivo proti meningokokom skupin A, C, W-135 in Y, konjugirano
Nimenrix should be used according to available official recommendations.
Cepivo Nimenrix se mora uporabljati v skladu z razpoložljivimi uradnimi priporočili.
Nimenrix was compared with several other similar vaccines against N. meningitidis in people aged 12 months or more.
Cepivo Nimenrix so primerjali z različnimi drugimi podobnimi cepivi proti bakteriji N. meningitidis pri ljudeh, starejših od 12 mesecev.
Nimenrix will be given to you by a doctor or nurse.
Cepivo Nimenrix vam bo dal zdravnik ali medicinska sestra.
Nimvastid 1.5 mg hard capsules Rivastigmine
Nimvastid 1,5 mg trde kapsule rivastigmin
Nimvastid 1.5 mg hard capsules, which contain a white to almost white powder, have a yellow cap and yellow body.
Nimvastid 1,5 mg trde kapsule, ki vsebujejo bel do skoraj bel prašek, imajo rumen pokrovček in rumeno telo kapsule.
Nimvastid 1.5 mg orodispersible tablets Rivastigmine
Nimvastid 1,5 mg orodisperzibilne tablete rivastigmin
Nimvastid 3 mg
Nimvastid 3 mg.
Nimvastid 3 mg hard capsules Rivastigmine
Nimvastid 3 mg trde kapsule rivastigmin
Nimvastid 3 mg orodispersible tablets Rivastigmine
Nimvastid 3 mg orodisperzibilne tablete rivastigmin
Nimvastid 4.5 mg
Nimvastid 4,5 mg.
Nimvastid 4.5 mg hard capsules Rivastigmine
Nimvastid 4,5 mg trde kapsule rivastigmin
Nimvastid 4.5 mg orodispersible tablets Rivastigmine
Nimvastid 4,5 mg orodisperzibilne tablete rivastigmin
Nimvastid 6 mg
Nimvastid 6 mg.
Nimvastid 6 mg hard capsules Rivastigmine
Nimvastid 6 mg trde kapsule rivastigmin
Nimvastid 6 mg orodispersible tablets Rivastigmine
Nimvastid 6 mg orodisperzibilne tablete rivastigmin
Nimvastid is a ‘generic medicine’.
Zdravilo Nimvastid je „generično zdravilo“.
Nimvastid is used for the treatment of adult patients with mild to moderately severe Alzheimer’s dementia, a progressive brain disorder that gradually affects memory, intellectual ability and behaviour.
Zdravilo Nimvastid uporabljamo za zdravljenje odraslih bolnikov z blago do zmerno hudo Alzheimerjevo demenco, to je napredujoča bolezen možganov, ki postopoma prizadene spomin in intelektualne sposobnosti ter vpliva na vedenje bolnika.
Nimvastid is used for the treatment of patients with mild to moderately severe Alzheimer’s dementia, a progressive brain disorder that gradually affects memory, intellectual ability and behaviour.
Zdravilo Nimvastid se uporablja za zdravljenje bolnikov z blago do zmerno hudo alzheimerjevo demenco, napredujočo okvaro možganov, ki postopoma prizadene spomin, intelektualne zmožnosti in vedenje.
Nimvastid should not be used during pregnancy unless clearly necessary.
Zdravila Nimvastid v času nosečnosti ne smete uporabljati, če to ni nujno potrebno.
Nine cases of inappropriate schedule of drug administration were reported cumulatively with degarelix.
Poročali so o skupno devetih primerih neprimerne sheme odmerjanja zdravila z zdravilno učinkovino degareliks.
Nine of 17 ALL patients were treated with clofarabine 52 mg/m2/day.
Devet izmed 17 bolnikov z ALL je prejemalo 52 mg/m2 klofarabina na dan.
Nine of the cases reported were associated with adverse events (AEs).
Devet od navedenih primerov je bilo povezanih z neželenimi učinki (AE).
Nine of these patients had pulmonary embolisms, one was Grade 2 and eight were Grade 4.
Devet od teh bolnikov je imelo pljučno embolijo: en 2. stopnje in osem 4. stopnje.